Overview
ENLV market data
Price History
ENLV price chart
Valuation & Profitability
- P/E (TTM)
- 0.09 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $382.11 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.41 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.42 – $31.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $113.1 · P/B 0.01.
Company news
Enlivex shares are trading higher after the company announced its RAIN token holdings.Benzinga · Jul 20, 2026, 1:01 PM
Enlivex Updates RAIN Token Holings; Net Asset Value Per Ordinary Share $66.16; Company Held 79,550,593,122 RAIN Tokens Valued At ~$1.1BBenzinga · Jul 20, 2026, 12:04 PM
FDA Grants Enlivex Regenerative Medicine Advanced Therapy Designation To AllocetraBenzinga · Jul 13, 2026, 12:04 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jul 9, 2026, 1:01 PM
Enlivex Effects 1-for-15 Reverse Stock Split July 9, 2026Benzinga · Jul 7, 2026, 12:10 PM
Enlivex Holds 79.569B RAIN Token With Total Value Of ~$1.14BBenzinga · Jun 22, 2026, 12:55 PM
Enlivex Receives Australian Patent Entitled 'Therapeutic Apoptotic Cells For Treatment Of Osteoarthritis'Benzinga · Jun 15, 2026, 12:10 PM
RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 LaunchGlobenewswire Inc · Jun 5, 2026, 7:15 PM
Enlivex To Feature Extended 3-Month And 6-Months Clinical Data In Knee Osteoarthritis Phase Iia Trial At EULAR European Congress Of RheumatologyBenzinga · Jun 1, 2026, 12:13 PM
EnLivex Doses First Patient In Its Phase 2b Clinical Trial Of Allocetra For Treatment Of Patients With Moderate-to-Severe Age-Related Symptomatic Primary Knee OsteoarthritisBenzinga · May 18, 2026, 12:10 PM